Moderna first announced it would scale down manufacturing of its COVID-19 vaccine, Spikevax, in late 2023, including at contract drug manufacturer Lonza's facility in Switzerland, as part of a ...
Moderna first announced it would scale down manufacturing of its Spikevax COVID-19 vaccine in late 2023, including at contract drug manufacturer Lonza's facility in Switzerland, as part of an ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.
PORTSMOUTH — The Pease Development Authority’s Board of Directors voted to approve the concept plan for Lonza Biologics Inc., ...
Moderna norovirus vaccine trial on hold by US ... struggling economy amid heightened political risks. December 12, 2024 Lonza seeks deals as it exits health and ingredients to focus on contract ...
Lonza's sales for 2024 were CHF 6.6 billion ... Sales were impacted by the loss of covid-related mRNA revenue from the termination of Moderna’s contract. However, after adjusting for this ...
Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback